Journal article
SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants
- Abstract:
-
SB 9200 is a novel, first-in-class oral modulator of innate immunity that is believed to act via the activation of the RIG-I and NOD2 pathways. SB 9200 has broad-spectrum antiviral activity against RNA viruses including hepatitis C virus (HCV), norovirus, respiratory syncytial virus, and influenza and has demonstrated activity against hepatitis B virus (HBV) in vitro and in vivo. In phase I clinical trials in chronically infected HCV patients, SB 9200 has been shown to reduce HCV RNA by up to...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
Bibliographic Details
- Publisher:
- Wiley Publisher's website
- Journal:
- Journal of Medical Virology Journal website
- Volume:
- 89
- Issue:
- 9
- Pages:
- 1620-1628
- Publication date:
- 2017-03-17
- Acceptance date:
- 2017-02-24
- DOI:
- ISSN:
-
0146-6615 and 1096-9071
- Pmid:
-
28303593
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:1003682
- UUID:
-
uuid:69124fe4-5f5a-451f-9396-f9b044c4fba9
- Local pid:
- pubs:1003682
- Source identifiers:
-
1003682
- Deposit date:
- 2019-10-24
Terms of use
- Copyright date:
- 2017
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record